Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Anti-obesity drug Mounjaro is set rack up sales of nearly £22bn a year by 2030. But Trump's 'America First' policies mean Britons could soon be paying more for the 'King Kong' of weight-loss jabs ...

Anti-obesity ... While the burden to the NHS might be limited due to the way contracts are negotiated, private suppliers could be more vulnerable to price rises. Eli Lilly is set to make $27bn ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a landscape of robust demand for its groundbreaking diabetes and obesity ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a landscape of robust demand for its groundbreaking diabetes and obesity ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

The company's head of obesity said the ultimate goal is to develop a once-per-year shot. Imagine this: You walk into your doctor and get your yearly flu vaccine and a yearly dose of your weight-loss ...

To address this, American pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven effective in managing both obesity and type-2 diabetes.

This indicates there remains much potential in the molecules used as the basis for obesity drugs -- semaglutide for Novo Nordisk, and tirzepatide in the case of Eli Lilly. Waxing bullish about the ...